Redsense Q1 net sales rise, helped by higher usage

Redsense Medical AB (publ)

20/05/2026 07:40

Overview

Blood leakage monitor maker's Q1 net sales rose yr/yr, company returned to profit

Company attributes growth to increased usage and broader adoption of installed systems

First Clamp System sale completed in UK clinic during Q1

Outlook

Company aims to increase end-customer usage in the U.S. and expand into new markets in 2026

Redsense plans to progress rollout of the Clamp and support broader adoption in 2026

Company expects stronger operational base and commercial approach to support continued growth

Result Drivers

INCREASED USAGE - Co said higher sales of disposables indicated increased usage of previously installed systems and strengthened underlying demand

REVISED PRICING STRUCTURE - Co said new U.S. pricing, with lower per-treatment consumable cost, supported broader adoption and contributed to higher usage

INVENTORY PRICING RECONCILIATION - Part of Q1 sales increase reflected a reconciliation of pricing on existing U.S. inventory ahead of the change

Company press release: ID:nWkr84qvHj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 6.40 mln
Q1 EPS
SEK 0.07
Q1 Net Income
SEK 1.12 mln
Q1 EBIT
SEK 1.08 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)